Provectus Biopharmaceuticals, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-982.6K | $-1.3M | $-1.2M | $-1.3M | $-1.8M | $-1.1M | $-2.4M | $-1.0M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $466 | $466 | $465 | $466 | $465 | $467 | $466 | $2.2K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $305.9K | $306.1K | $287.6K | $312.8K | $322.1K | $315.1K | — | — |
| Net Cash from Operating Activities | $-358.2K | $-357.6K | $-869.6K | $-839.9K | $-523.1K | $-1.1M | $-912.0K | $-565.0K |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | — | — | — | — | — | — | — |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $1.3M | $329.9K | $1.0M | $495.9K | $469.8K | $1.1M | $788.4K | $589.4K |
| Net Change in Cash | $933.0K | $-27.4K | $178.8K | $-344.0K | $-53.0K | $-20.3K | $-124.5K | $24.9K |
| Free Cash Flow | — | — | — | — | — | — | — | — |